ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 0 مورد

Management of cutaneous immune-related adverse events from immune checkpoint inhibitor therapy

Management of cutaneous immune-related adverse events from immune checkpoint inhibitor therapy

GABA: gamma-aminobutyric acid; ICI: immune checkpoint inhibitor; IL: interleukin; NBUVB: narrowband ultraviolet B; OTC: over the counter; TNF: tumor necrosis factor.

* Additional biologic agents suggested by UpToDate for the treatment of bullous pemphigoid include dupilumab and omalizumab, with dupilumab preferred for long-term use.

From: Phillips GS, Wu J, Hellmann MD, et al. Treatment Outcomes of Immune-Related Cutaneous Adverse Events. J Clin Oncol 2019; 37:2746. DOI: 10.1200/JCO.18.02141. Copyright © 2019 American Society of Clinical Oncology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.
Graphic 134200 Version 2.0